Relations (1)

related 6.00 — strongly supporting 6 facts

Ketamine is a pharmacological intervention used for the rapid treatment of Major Depressive Disorder, as evidenced by clinical meta-analyses [1] and systematic reviews [2]. Research indicates that ketamine administration in these patients induces neuroplasticity [3], alters default mode connectivity [4], and enhances sensory evoked potential long-term potentiation [5], with subjective effects linked to treatment response [6].

Facts (6)

Sources
The Montreal model: an integrative biomedical-psychedelic ... frontiersin.org Frontiers in Psychiatry 3 facts
referenceHan et al. published a meta-analysis in 2016 in Neuropsychiatric Disease and Treatment on the efficacy of ketamine for the rapid treatment of major depressive disorder, based on randomized, double-blind, placebo-controlled studies.
referenceEvans et al. (2018) measured default mode connectivity in patients with major depressive disorder up to 10 days following the administration of ketamine, as published in Biological Psychiatry.
referenceMathai et al. (2020) performed a systematic review on the relationship between subjective effects induced by a single dose of ketamine and the subsequent treatment response in patients with major depressive disorder.
Effects of psychedelics on neurogenesis and broader neuroplasticity link.springer.com Springer 2 facts
claimKetamine treatment in patients with major depressive disorder induces plasticity, as indicated by concomitant changes in Brain-Derived Neurotrophic Factor (BDNF) levels and sleep slow waves.
referenceThere is a relationship between subjective effects induced by a single dose of ketamine and the treatment response in patients with major depressive disorder.
Neuroimaging in psychedelic drug development: past, present, and ... nature.com Nature 1 fact
referenceSumner RL, McMillan R, Spriggs MJ, Campbell D, Malpas G, Maxwell E, et al. authored 'Ketamine Enhances Visual Sensory Evoked Potential Long-term Potentiation in Patients With Major Depressive Disorder', published in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging in 2020, volume 5, pages 45–55.